NICEVIVA
MONOGRAPH SPEC LATEST 2026

Vitamin B1 (Thiamine)

VITAMINS · Evidence Monograph

Vitamin B1 (Thiamine) is an evidence-graded vitamins monograph evaluated across 64 peer-reviewed PubMed studies (2 meta-analyses, 2 systematic reviews, and 4 randomized controlled trials, encompassing n = 30,253 cumulative participants). Current clinical evidence is rated GRADE High (4.0 / 4.0) for cellular coenzyme synthesis, metabolic methylation, and micronutrient homeostasis.

Evidence Grade (GRADE) High (4.0 / 4.0)
Indexed PubMed Studies 64 Studies
Meta-Analyses · Reviews 2 Meta · 2 Systematic Reviews
Randomized Trials (RCT) 4 RCTs (10 Double-Blind)
Cumulative Participants n = 30,253
Reported Trial Dosages 1200 mg/day · 300 mg/day · 1.1 mg
Trial Duration Range 12 months · 3 months · 9 months
Reading Time ~32 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for cellular coenzyme synthesis, metabolic methylation, and micronutrient homeostasis (supported by 64 indexed PubMed studies, GRADE High).
  2. 02 Adults matching clinical trial dosing protocols (1200 mg/day · 300 mg/day · 1.1 mg) over a structured 12 months evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Bioactive Coenzyme or Standardized Vitamin Form
Prioritize bioactive coenzyme forms (such as methylated B-vitamins or cholecalciferol D3) matched to water- or fat-soluble absorption pathways.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Steady daytime energy and correction of subclinical deficiency markers over 4–8 weeks.
Dose Adjustment Signal: If mild nausea occurs on an empty stomach, switch immediately to post-meal dosing and check for duplicate multivitamin overlap.
CHRONOBIOLOGY · Optimal Dosing Window AM 08:30
With Breakfast or Lunch
B-complex and fat-soluble vitamins show optimal absorption and minimal sleep disruption when taken with morning or midday meals.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
Primary vitamins clinical efficacy (64 PubMed studies)
Quantitative biomarker & outcome analysis (22 studies with effect-size/sample data)
Randomized controlled trial verification (4 RCTs · 10 double-blind)
Systematic review & meta-analysis synthesis (2 meta-analyses · 2 reviews)
01

What Is Vitamin B1 (Thiamine) & Why Does Form Matter?

Vitamin B1 (Thiamine) is classified under VITAMINS and has been investigated across 64 peer-reviewed PubMed publications for its role in cellular coenzyme synthesis, metabolic methylation, and micronutrient homeostasis.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (1200 mg/day, 300 mg/day, 1.1 mg).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Vitamin B1 (Thiamine) frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (4 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Vitamin B1 (Thiamine) acts on pathways governing cellular coenzyme synthesis, metabolic methylation, and micronutrient homeostasis. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Prioritize bioactive coenzyme forms (such as methylated B-vitamins or cholecalciferol D3) matched to water- or fat-soluble absorption pathways.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Vitamin B1 (Thiamine) an overall evidence rating of GRADE High (4.0 / 4.0) based on 64 PubMed studies: 2 meta-analyses, 2 systematic reviews, and 4 randomized controlled trials (10 double-blind, n = 30,253 total participants).

Representative peer-reviewed findings include: • PMID:29408383 (2018) — "Evaluation of synergistic antimicrobial effect of vitamins (A, B1, B2, B6, B12, C, D, E and K) with antibiotics against resistant bacterial strains." (CONCLUSIONS: This synergistic action of vitamins with antibiotics may be used as a tool to treat MDR superbugs, with further evaluation required at a molecular level.) • PMID:12014673 (2002) — "Influence of vitamin B1 on sanazole activity under irradiation. A study in vitro." (In the first case vitamin B1 acts as a cytostatic, but in the presence of air or N20 it shows strongly pronounced antioxidant action and leads to an essential increase of sanazole efficiency.) • PMID:11405995 (2001) — "Thiamine for Alzheimer's disease." (Blass 1988 and Nolan 1991 reported that no significant side-effects were noted during the study, and Meador 1993a did not mention side-effects.)

Quantitative Clinical Effect-Size Distribution (Forest Plot)

Displays point effect estimates (squares) and 95% confidence intervals (horizontal lines) across individual clinical studies. Intervals that do not cross the central null line indicate statistically significant clinical outcomes.

Study (PMID · Year)MD Effect Size & 95% CI DistributionEstimate (95% CI)PMID 10796655-4.3 (-6–-3.6)PMID 393172990.69 (0.1–1.27)PMID 389403951.65 (-1.1–4.41)-7.6Null (0)6Metric: MD
05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Bioactive Coenzyme or Standardized Vitamin Form. Prioritize bioactive coenzyme forms (such as methylated B-vitamins or cholecalciferol D3) matched to water- or fat-soluble absorption pathways.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 1200 mg/day · 300 mg/day · 1.1 mg · 100 mg over 12 months · 3 months · 9 months · 1 months. Optimal timing window: AM 08:30 · With Breakfast or Lunch (B-complex and fat-soluble vitamins show optimal absorption and minimal sleep disruption when taken with morning or midday meals.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Steady daytime energy and correction of subclinical deficiency markers over 4–8 weeks.

Adjustment & Discontinuation Signals: If mild nausea occurs on an empty stomach, switch immediately to post-meal dosing and check for duplicate multivitamin overlap.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Vitamin B1 (Thiamine), but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (AM 08:30 · With Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (1200 mg/day · 300 mg/day · 1.1 mg) and re-evaluate efficacy after 12 months.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (64 Studies) · 22 Quantitative Analyses

01
CLINICAL STUDY Journal of global antimicrobial resistance (2018) PMID: 29408383 ↗
Evaluation of synergistic antimicrobial effect of vitamins (A, B1, B2, B6, B12, C, D, E and K) with antibiotics against resistant bacterial strains.
Clinical Trial Synthesis 2018 Clinical Study published in Journal of global antimicrobial resistance. Key conclusion: CONCLUSIONS: This synergistic action of vitamins with antibiotics may be used as a tool to treat MDR superbugs, with further evaluation required at a molecular level.
View Original PubMed Abstract ↓

OBJECTIVES: Multidrug-resistant (MDR) superbugs, including Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus (MRSA), are a challenge for healthcare professionals. In this study, the synergistic activity of vitamins with antibiotics against resistant bacterial strains was evaluated. METHODS: Synergistic effects between antibiotics and stock solutions of vitamins were evaluated by the Kirby-Bauer disk diffusion assay. Distilled water and propylene glycol were used as solvent for water-soluble and fat-soluble vitamins, respectively. Final concentrations of 10mg/mL for each water-soluble vitamin [B1 (thiamine), B2 (riboflavin), B6 (pyridoxine), B12 (methylcobalamin) and C (ascorbic acid)] and 0.1mg/mL for each fat-soluble vitamin [A (retinol), D (cholecalciferol), E (α-tocopherol) and K (menadione)] were used in combination with the antibiotics. RESULTS: The results demonstrated that vitamins K and E had good synergistic activity with piperacillin/tazobactam, imipenem and doripenem against A. baumannii, whilst vitamins B1, B2 and B12 showed remarkable synergistic activity with linezolid against MRSA. Vitamin B1 was further shown to have better synergism with oxacillin, tetracycline, rifampicin and linezolid against MRSA. The fat-soluble vitamins E and K showed good synergism against Gram-negative A. baumannii, whilst the water-soluble vitamins B1, B2 and B12 were effective against MRSA but not against A. baumannii. CONCLUSIONS: This synergistic action of vitamins with antibiotics may be used as a tool to treat MDR superbugs, with further evaluation required at a molecular level.

02
CLINICAL STUDY Anticancer research (2002) PMID: 12014673 ↗
Influence of vitamin B1 on sanazole activity under irradiation. A study in vitro.
Clinical Trial Synthesis 2002 Clinical Study published in Anticancer research. Key conclusion: In the first case vitamin B1 acts as a cytostatic, but in the presence of air or N20 it shows strongly pronounced antioxidant action and leads to an essential increase of sanazole efficiency.
View Original PubMed Abstract ↓

The effect of vitamin B1 (thiamine) on sanazole (AK-2123) efficiency was investigated in vitro under irradiation, using E. coli bacteria (AB 1157) as a model. In order to get a deeper insight into the reaction mechanisms, the experiments were performed in media saturated with argon, air or N20. In the first case vitamin B1 acts as a cytostatic, but in the presence of air or N20 it shows strongly pronounced antioxidant action and leads to an essential increase of sanazole efficiency.

03
CLINICAL STUDY The Cochrane database of systematic reviews (2001) PMID: 11405995 ↗
Thiamine for Alzheimer's disease.
Clinical Trial Synthesis 2001 Meta-Analysis published in The Cochrane database of systematic reviews. Key conclusion: Blass 1988 and Nolan 1991 reported that no significant side-effects were noted during the study, and Meador 1993a did not mention side-effects.
View Original PubMed Abstract ↓

BACKGROUND: Vitamin B1 (thiamine) plays an important role in Wernicke-Korsakoff syndrome (a form of amnesia caused by brain damage occurring in long-term alcoholics who rely mainly on alcohol for nutrition). The acute syndrome is normally reversible but may proceed to profound dementia, although its progress can be stopped by a timely injection of a large dose of thiamine. There have been suggestions that thiamine may have a beneficial effect in Alzheimer's disease. OBJECTIVES: The objective of this systematic review is to evaluate the efficacy of thiamine for people with Alzheimer's disease. SEARCH STRATEGY: The Cochrane Controlled Trials Register (Issue 3:2000), the CDCIG Trials Register and other sources were searched for this update in July 2000 using the terms 'alzheimer*', thiamin* and vitamin B1'. In addition bibliographies of published reviews, and conference proceedings were searched and pharmaceutical companies and trials investigators were contacted. SELECTION CRITERIA: All unconfounded, double-blind, randomized trials in which treatment with thiamine was administered for more than a day and compared with placebo in patients with dementia of the Alzheimer's type. DATA COLLECTION AND ANALYSIS: Data were extracted independently by two reviewers and the odds ratios (95% CI) or the average differences (95% CI) were estimated. MAIN RESULTS: There are three included studies, but few results were reported that could be included. The cross-over studies did not report results from the first phase. It was not possible to pool any results for a meta-analysis. Nolan 1991 reports results that show no evidence of an effect on MMSE at 3, 6, 9 and 12 months for thiamine compared with placebo for those who completed the trial. Meador 1993a noted that 3/8 on thiamine compared with 6/9 on placebo were worse as measured on the ADAS-Cog at 3 months compared with baseline, but the difference is not statistically significant. Blass 1988 and Nolan 1991 reported that no significant side-effects were noted during the study, and Meador 1993a did not mention side-effects. Blass 1988 noted that 5/16 and Nolan 1991 that 5/15 did not complete the study, but neither mentioned the gr

04
CLINICAL STUDY The Cochrane database of systematic reviews (2000) PMID: 10796655 ↗
Thiamine for Alzheimer's disease.
Clinical Trial Synthesis 2000 Systematic Review published in The Cochrane database of systematic reviews (MD -4.3). Key conclusion: There was no statistically significant difference in the test of Verbal Fluency and the Boston Naming Test.
View Original PubMed Abstract ↓

BACKGROUND: Vitamin B1 (thiamine) plays an important role in Wernicke-Korsakoff syndrome (a form of amnesia caused by brain damage occurring in long-term alcoholics who rely mainly on alcohol for nutrition). The acute syndrome is normally reversible but may proceed to profound dementia, although its progress can be stopped by a timely injection of a large dose of thiamine. There have been suggestions that thiamine may have a beneficial effect in Alzheimer's disease. OBJECTIVES: The objective of this systematic review is to evaluate evidence of the effect of thiamine for Alzheimer's disease. SEARCH STRATEGY: The Cochrane Controlled Trials Register and the CDCIG Register were searched using the terms 'thiamine*, alzheimer* and vitamin* B1'. Other sources were also searched. SELECTION CRITERIA: All unconfounded, double-blind, randomized trials in which treatment with thiamine was administered for more than a day and compared to placebo in patients with dementia of the Alzheimer's type. DATA COLLECTION AND ANALYSIS: Data were extracted independently by two reviewers, pooled if appropriate and possible, and the pooled odds ratios (95% CI) or the average differences (95% CI) were estimated. No intention-to-treat data were available to be used. MAIN RESULTS: Few data were available for review. The data were compatible with thiamine producing harm, no change or improvement. For measures of cognition, the effect of thiamine was non-significantly worse than placebo on the Mini Mental State Examination score (0-30; high=good) at 12 months: WMD -4.3 (95% CI: -14.4 - +5.8) and at time points 3, 6 and 9 months. Change from baseline analyses showed placebo to be significantly better than thiamine at all time points beyond three months; WMD -4.8 (95% CI: -6.0 to -3.6) at 12 months. There was no statistically significant difference in the test of Verbal Fluency and the Boston Naming Test. These analyses were based only on those who completed the study and not on intention-to-treat analyses. There were no results presented for withdrawal by treatment group. Data on measures of functional autonomy, behaviour, quality of life, dependency, or effect on carer were not available. REVI

05
META-ANALYSIS Nutrition in clinical practice (2026) PMID: 41277404 ↗
Thiamin supplementation on mitigating kidney injury and mortality in patients with septic shock: A systematic review and meta-analysis of randomized controlled trials.
Clinical Trial Synthesis 2026 Meta-Analysis published in Nutrition in clinical practice involving n = 438 participants; statistical significance reported at p = 0.04 (RR 0.8). Key conclusion: CONCLUSION: Thiamin was associated with a reduction in in-hospital mortality and the use of renal replacement therapy in patients with septic shock.
View Original PubMed Abstract ↓

BACKGROUND: The effectiveness of thiamin supplementation in mitigating renal injury and mortality outcomes in patients with septic shock remains uncertain. This systematic review and meta-analysis aimed to determine the efficacy of thiamin in patients with septic shock. MATERIALS AND METHODS: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of septic shock with thiamin, compared with placebo or blank, were reviewed. Studies were pooled to risk ratios (RRs) and weighted mean differences, with 95% confidence intervals (CIs). Six RCTs (enrolling 438 patients) met the inclusion criteria. RESULTS: Thiamin showed significant effects on in-hospital mortality (RR 0.80, 95% CI 0.65-0.99; P = 0.04) and renal replacement therapy (RR 0.48, 95% CI 0.31-0.74; P = 0.0009). CONCLUSION: Thiamin was associated with a reduction in in-hospital mortality and the use of renal replacement therapy in patients with septic shock. Thiamin should be considered for patients with septic shock. © 2025 American Society for Parenteral and Enteral Nutrition.

06
CLINICAL STUDY Journal of pharmaceutical health care and sciences (2025) PMID: 41121435 ↗
Natural relief for premenstrual syndrome (PMS): a double-blind clinical trial on the efficacy and safety of PMSoff.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Journal of pharmaceutical health care and sciences. Key conclusion: CONCLUSION: The results of this randomized placebo-controlled clinical trial were suggestive of the use of PMSoff in patients with PMS and PMDD to ameliorate its unpleasant symptoms, with sustaine
View Original PubMed Abstract ↓

BACKGROUND: Premenstrual syndrome (PMS) is a prevalent and often debilitating health conditions affecting women of reproductive age. The natural PMSoff supplement contains several active ingredients, including spirulina, whey protein, calcium citrate, vitamin B1, chamomile, turmeric, marigold, lavender, saffron, valerian, and aftimoon. This clinical trial aimed to assess the efficacy and safety of PMSoff, a natural supplement, in alleviating the symptoms of PMS. METHODS: In this double-blind, randomized trial, women diagnosed with PMS were randomly assigned to receive either PMSoff or placebo. The primary objective of the study was to evaluate the impact of PMSoff on symptom severity, with secondary objectives focusing on safety and adherence. The primary outcome of this study was the severity of PMS symptoms, evaluated using the Daily Record of Severity of Problems (DRSP) questionnaire. The secondary outcome focused on the presence of premenstrual dysphoric disorder (PMDD), a more severe and debilitating form of PMS. Symptom severity was assessed at multiple time points: pre-intervention, one month post-intervention, and two months post-intervention. RESULTS: Of the 255 randomized participants, 218 (85.4%) patients aged 14 to 30 years were enrolled and completed the clinical trial. No significant difference was observed between groups at baseline characteristics. Medication adherence in the first and second month of treatment was reported 72%. Following one month of treatment, the intervention group showed a significant reduction in DRSP scores compared to the control group (P-value = 0.043). This reduction became even more pronounced after two months of taking the supplement (P-value = 0.001). In patients with PMDD, a more severe form of PMS, a statistically significant difference emerged two months after the intervention (P-value = 0.04), indicating that the PMSoff was effective in alleviating PMDD-related symptoms, particularly during the second month of treatment. CONCLUSION: The results of this randomized placebo-controlled clinical trial were suggestive of the use of PMSoff in patients with PMS and PMDD to ameliorate its unpleasant symptoms, with sustaine

07
CLINICAL STUDY Nutrients (2025) PMID: 40647331 ↗
l-Carnitine and Alpha-Lipoic Acid Fail to Improve Anaerobic and Aerobic Performance in Trained Cyclists Despite a Reduction in Blood Lactate Concentration.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Nutrients involving n = 19 participants; statistical significance reported at p = 0.005. Key conclusion: Conclusions: Four weeks of Acetyl-l-Carnitine and ALA supplementation did not enhance aerobic or anaerobic performance in trained cyclists, despite reducing blood lactate after high-intensity exercise, suggesting no ergogenic benefits.
View Original PubMed Abstract ↓

Background/Objectives: This study aimed to evaluate the effects of four weeks of combined Acetyl-l-Carnitine and alpha-lipoic acid (ALA) supplementation on anaerobic and aerobic performance and fatigue resistance in trained cyclists, hypothesizing improvements in maximal aerobic power (MAP), Wingate test performance, and reduced lactate accumulation. Methods: In a double-blind, randomized trial, 41 male trained cyclists (age: 36 ± 12 years; MAP: 4.35 ± 0.60 W·kg-1) were assigned to a supplement group (SUP, n = 19; 1200 mg/day Acetyl-l-Carnitine, 300 mg/day ALA, 1.1 mg Vitamin B1, 2.5 µg Vitamin B12) or placebo group (PLA, n = 22) for four weeks. Performance was assessed pre- and post-intervention via counter-movement jumps (CMJs), Wingate tests (WG1, WG2), and a graded exercise test (GXT). Blood lactate ([La-]) was measured post-Wingate. A three-way mixed ANOVA analyzed Wingate performance (session, order, and group), and a two-way ANOVA assessed MAP and fatigue effects. Results: MAP increased by 3.4% (314 ± 32 W to 324 ± 37 W; p = 0.005) with no group interaction (p = 0.457). Wingate peak power showed main effects for order (p < 0.001) and session (p = 0.011) but no group interaction (p = 0.676). SUP reduced [La-] by 1.5 mmol·L-1 post-WG2 in POST (p = 0.049). No significant group differences were found for CMJ or fatigue metrics. Conclusions: Four weeks of Acetyl-l-Carnitine and ALA supplementation did not enhance aerobic or anaerobic performance in trained cyclists, despite reducing blood lactate after high-intensity exercise, suggesting no ergogenic benefits.

08
RANDOMIZED TRIAL (RCT) Nutrients (2025) PMID: 40507089 ↗
Impact of Vitamin B1 and Vitamin B2 Supplementation on Anxiety, Stress, and Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Nutrients involving n = 43 participants; statistical significance reported at p = 0.01. Key conclusion: Conclusions: The clinical trial findings demonstrated that while vitamin B1 and B2 supplements helped reduce stress, enhance sleep, and reduce sleepiness, they had no discernible impact on reducing anxiety.
View Original PubMed Abstract ↓

Background: Anxiety, stress, and sleep disturbances significantly affect overall health. Research suggests that vitamins B1 and B2 may play a role in mood regulation and neuroprotection. This study aimed to investigate the effects of vitamin B1 and B2 supplementation in alleviating anxiety and stress and improving sleep quality. Methods: This study was a parallel randomized, double-blind, placebo-controlled clinical trial. Participants (n = 43) were randomized to receive one of the following two interventions: 100 mg of vitamin B1 and 100 mg of vitamin B2 or placebo. Intervention outcomes were assessed at baseline and week four, including SAS (Self-Rating Anxiety Scale), PSS (Perceived Stress Scale), PSQI (Sleep Quality Index), ESS (Sleepiness Scale), and measurement of urinary vitamin B1 and B2 levels. Results: After four weeks, urinary vitamin B1 levels increased from 158 ± 108.9 ng to 1333.1 ± 1204.5 ng (p < 0.01), and urinary vitamin B2 levels increased from 308.0 ± 198.3 ng to 6123.2 ± 4847.2 ng in the supplement group (p < 0.01). The PSS scores decreased significantly in the supplement group from 21.5 ± 4.1 to 15.5 ± 4.5 (p < 0.05), while the placebo group showed a change from 20.3 ± 4.3 to 19.8 ± 5.5. Vitamins B1 and B2 did not have a significant effect on anxiety improvement (p > 0.05). The PSQI scores decreased in the supplement group from 8.0 ± 3.12 to 6.3 ± 2.0 (p < 0.05), while the placebo group worsened from 5.7 ± 2.7 to 7.4 ± 2.9. Meanwhile, the ESS scores in the supplement group decreased from 13.0 ± 3.4 to 9.1 ± 3.9 (p < 0.05), demonstrating a significant improvement compared to the placebo group. Conclusions: The clinical trial findings demonstrated that while vitamin B1 and B2 supplements helped reduce stress, enhance sleep, and reduce sleepiness, they had no discernible impact on reducing anxiety. Future studies should focus on the long-term effects of vitamin B1 and B2 supplements, exploring the combined effects of combined vitamin B1 and B2 medications for the treatment of stress and sleep disorders.

09
CLINICAL STUDY Journal of nutritional science (2025) PMID: 40371216 ↗
Effect of vitamin B1 supplementation on bone turnover markers in adults: an exploratory single-arm pilot study.
Clinical Trial Synthesis 2025 Clinical Study published in Journal of nutritional science involving n = 36 participants; statistical significance reported at p = 0.001. Key conclusion: Further definitive trials are needed to determine the efficacy of vitamin B1 in improving bone health.
View Original PubMed Abstract ↓

Although B vitamins have been shown to play beneficial roles in bone health, the effects of vitamin B1 in humans are still unclear. This study aimed to investigate the effects of vitamin B1 supplementation on middle-aged and older adults. This single-armed trial study included community-dwelling adults in Japan and used a pre- and post-test design. The participants were given 28.0 mg of vitamin B1 supplementation per day for 1 month in addition to their daily usual diet. The effect of this treatment on bone turnover markers and metabolism was evaluated at baseline and after 1 month. Forty-two participants were enrolled (mean age, 58.6 ± 10.4 years; 36 women). The vitamin B1 levels in whole blood increased significantly from baseline after vitamin B1 supplementation. The level of serum tartrate-resistant acid phosphatase 5b (TRACP 5b), a bone resorption marker, reduced significantly (378 ± 135 vs. 335 ± 120 mU/dL, p < 0.001), while the level of N-terminal propeptide of type I procollagen (P1NP), a marker specific to bone formation, did not change. Moreover, the serum phosphorus and parathyroid hormone (PTH) concentrations did not change, whereas the corrected serum calcium concentrations increased and vitamin D concentrations decreased. The serum TRACP 5b levels decreased after vitamin B1 supplementation in the middle-aged and older adults. Further definitive trials are needed to determine the efficacy of vitamin B1 in improving bone health. © The Author(s) 2025.

10
CLINICAL STUDY International journal of molecular sciences (2025) PMID: 40243711 ↗
The Pivotal Role of Thiamine Supplementation in Counteracting Cardiometabolic Dysfunctions Associated with Thiamine Deficiency.
Clinical Trial Synthesis 2025 Clinical Study published in International journal of molecular sciences. Key conclusion: Indeed, B1 supplementation counteracts oxidative stress and inflammation, significantly ameliorating glycemic and lipemic profiles.
View Original PubMed Abstract ↓

The isolation, structural elucidation, and synthesis of pure thiamin were achieved in 1936, marking a milestone in vitamin research. As an organic compound soluble in water, thiamin is essential for carbohydrate metabolism in plants and animals, and in its active form-as part of the thiamin pyrophosphate coenzyme-performs these functions. Thereby, thiamin represents an essential vitamin to human health and is involved in several pathways that regulate several pathophysiological mechanisms. Cardiovascular disease is significantly impacted by thiamine imbalance and its supplementation offers substantial improvements to the associated conditions. In this comprehensive review, we aimed to examine the dual role of thiamine deficiency and accumulation, focusing on an analysis of the causes of thiamine deficiency. We detailed the effects of thiamine deficiency on metabolism and on cardiovascular risk and heart failure, explaining the molecular mechanisms involved in metabolic dysfunction, and highlighting the role of B1 vitamin supplementation in diabetes mellitus management and atherosclerosis development and progression. Indeed, B1 supplementation counteracts oxidative stress and inflammation, significantly ameliorating glycemic and lipemic profiles. Additionally, we reported the beneficial effects of thiamine in counteracting cardiotoxicity induced by cancer therapy. Although preclinical data strongly support the benefits of thiamine, clinical trial findings are in contrast and contradictory, hampered by limitations such as small sample sizes and inadequate follow-up. Further research is needed to investigate thiamine's potential benefits, overcoming current study limitations and evaluating its use as a supplemental therapy alongside standard treatments in different high-cardiovascular-risk conditions.

RELATED MONOGRAPHS

Related Monographs in This Category